- Home
- OPOF vs ACRS Comparison
OPOF vs ACRS Comparison
Compare OPOF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPOF
- ACRS
- Stock Information
- Founded
- OPOF 1922
- ACRS 2012
- Country
- OPOF United States
- ACRS United States
- Employees
- OPOF N/A
- ACRS N/A
- Industry
- OPOF Major Banks
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- OPOF Finance
- ACRS Health Care
- Exchange
- OPOF Nasdaq
- ACRS Nasdaq
- Market Cap
- OPOF 200.6M
- ACRS 165.7M
- IPO Year
- OPOF N/A
- ACRS 2015
- Fundamental
- Price
- OPOF $39.63
- ACRS $1.45
- Analyst Decision
- OPOF
- ACRS Strong Buy
- Analyst Count
- OPOF 0
- ACRS 8
- Target Price
- OPOF N/A
- ACRS $9.71
- AVG Volume (30 Days)
- OPOF 17.1K
- ACRS 780.3K
- Earning Date
- OPOF 07-24-2025
- ACRS 08-06-2025
- Dividend Yield
- OPOF 1.38%
- ACRS N/A
- EPS Growth
- OPOF 55.28
- ACRS N/A
- EPS
- OPOF 1.96
- ACRS N/A
- Revenue
- OPOF $61,370,000.00
- ACRS $17,777,000.00
- Revenue This Year
- OPOF N/A
- ACRS N/A
- Revenue Next Year
- OPOF N/A
- ACRS $11.77
- P/E Ratio
- OPOF $20.78
- ACRS N/A
- Revenue Growth
- OPOF 5.28
- ACRS N/A
- 52 Week Low
- OPOF $13.70
- ACRS $1.05
- 52 Week High
- OPOF $40.95
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- OPOF 61.55
- ACRS 51.96
- Support Level
- OPOF $38.51
- ACRS $1.37
- Resistance Level
- OPOF $40.32
- ACRS $1.59
- Average True Range (ATR)
- OPOF 0.74
- ACRS 0.10
- MACD
- OPOF -0.06
- ACRS -0.01
- Stochastic Oscillator
- OPOF 93.37
- ACRS 28.57
About OPOF Old Point Financial Corporation
Old Point Financial Corp functions in the financial services domain in the United States. As the holding company of The Bank and Trust, it is a nationally chartered trust and wealth management service, provider. Its suite of services includes commercial banking solutions such as loan, deposit and cash management, which are rendered through a chain of branches throughout the country. It operates through segments such as Bank, Wealth and Company.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.